Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554

Verona Pharma (Nasdaq:VRNA) a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today positive top-line data from its Phase 2b study evaluating RPL554, a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 with bronchodilator and anti-inflammatory properties, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

As quoted in the press release:

The study met its primary endpoint, with RPL554 producing a clinically and statistically significant improvement in peak forced expiratory volume in one second (FEV₁) at four weeks in patients with moderate-to-severe COPD compared to placebo. Furthermore, the peak FEV₁was significantly improved at all time points over the four weeks of dosing. Secondary endpoints measuring 12 hour average FEV₁, COPD symptoms and Quality of Life were also met and support the potential clinical benefits of RPL554 for the treatment of COPD.

Click here to read the full press release.